Professor Kumlesh Dev
Professor, Physiology
Professor, Trinity Inst. of Neurosciences (TCIN)
Publications and Further Research Outputs
Peer-Reviewed Publications
Fagan SG, Bechet S, Dev KK. , Fingolimod Rescues Memory and Improves Pathological Hallmarks in the 3xTg-AD Model of Alzheimer's Disease , Mol Neurobiol, Online ahead print, 2022
Mekhaeil M, Dev KK, Conroy MJ. , Existing evidence for the repurposing of PARP-1 inhibitors in rare demyelinating diseases , Cancers, Online ahead print, 2022
Mampay M, Velasco-Estevez M, Rolle SO, Chaney AM, Boutin H, Dev KK, Moeendarbary E, Sheridan GK. , Spatiotemporal immunolocalisation of REST in the brain of healthy ageing and Alzheimer's disease rats., FEBS Open Bio, 11, 2021, p146 - 163
Velasco-Estevez, M. and Koch, N. and Klejbor, I. and Laurent, S. and Dev, K.K. and Szutowicz, A. and Sailer, A.W. and Rutkowska, A., Ebi2 is temporarily upregulated in mo3.13 oligodendrocytes during maturation and regulates remyelination in the organotypic cerebellar slice model, International Journal of Molecular Sciences, 22, (9), 2021
Velasco-Estevez M, Koch N, Klejbor I, Laurent S, Dev KK, Szutowicz A, Sailer AW, Rutkowska A. , EBI2 Is Temporarily Upregulated in MO3.13 Oligodendrocytes during Maturation and Regulates Remyelination in the Organotypic Cerebellar Slice Model. , Int J Mol Sci. , 22, 2021, p4342-
Clementino A, Velasco-Estevez M, Buttini F, Sonvico F, Dev KK. , Hybrid Nanoparticles as a Novel Tool for Regulating Psychosine-Induced Neuroinflammation and Demyelination In Vitro and Ex vivo., Neurotherapeutics, Online ahead print, 2021
Béchet S, O'Sullivan SA, Yssel J, Fagan SG, Dev KK., Fingolimod Rescues Demyelination in a Mouse Model of Krabbe's Disease., Journal of Neuroscience, 40, 2020, p3104 - 3118
Velasco-Estevez M, Rolle SO, Mampay M, Dev KK, Sheridan GK., Piezo1 regulates calcium oscillations and cytokine release from astrocytes., Glia, 68, 2020, p145 - 160
Velasco-Estevez M, Gadalla KKE, Liñan-Barba N, Cobb S, Dev KK, Sheridan GK., Inhibition of Piezo1 attenuates demyelination in the central nervous system., Glia, 68, 2020, p356 - 375
Neyman S, Braunewell K-H, O'Connell KE, Dev KK, Manahan-Vaughan D, Inhibition of the Interaction Between Group I Metabotropic Glutamate Receptors and PDZ-Domain Proteins Prevents Hippocampal Long-Term Depression, but Not Long-Term Potentiation, Frontiers in Synaptic Neuroscience, 11, 2019, p13
Rutkowska, A. and Shimshek, D.R. and Sailer, A.W. and Dev, K.K., EBI2 regulates pro-inflammatory signalling and cytokine release in astrocytes, Neuropharmacology, 133, 2018, p121-128
O'Sullivan, S.A. and O'Sullivan, C. and Healy, L.M. and Dev, K.K. and Sheridan, G.K., Sphingosine 1-phosphate receptors regulate TLR4-induced CXCL5 release from astrocytes and microglia, Journal of Neurochemistry, 2018
Velasco-Estevez M, Mampay M, Boutin H, Chaney A, Warn P, Sharp A, Burgess E, Moeendarbary E, Dev KK, Sheridan GK., Infection Augments Expression of Mechanosensing Piezo1 Channels in Amyloid Plaque-Reactive Astrocytes., Front Aging Neurosci, 2018, p332-
Dutta, P. and Dargahi, L. and O'Connell, K.E. and Bolia, A. and Ozkan, B. and Sailer, A.W. and Dev, K.K., A novel modelling mechanism of PAEL receptor and GABARAPL2 interaction involved in Parkinson's disease, Neuroscience Letters, 673, 2018, p12-18
Rutkowska, A. and Sailer, A.W. and Dev, K.K., EBI2 receptor regulates myelin development and inhibits LPC-induced demyelination, Journal of Neuroinflammation, 14, (1), 2017, p250-
O'Sullivan, S.A. and Dev, K.K., The chemokine fractalkine (CX3CL1) attenuates H
O'Sullivan S.A, Velasco-Estevez M, Dev K.K, Demyelination induced by oxidative stress is regulated by sphingosine 1-phosphate receptors, GLIA, 2017, p23148-
Dev K.K, Irving A.J, Lipid sensing G protein-coupled receptors in the CNS, Neuropharmacology, 113, 2017, p595 - 596
Misslin, C. and Velasco-Estevez, M. and Albert, M. and Oâ Sullivan, S.A. and Dev, K.K., Phospholipase A2 is involved in galactosylsphingosine-induced astrocyte toxicity, neuronal damage and demyelination, PLoS ONE, 12, (11), 2017, e0187217-
O'Sullivan S, Dev K.K, Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases, Neuropharmacology, 113, 2017, p597 - 607
Madill M, Fitzgerald D, O'Connell K.E, Dev K.K, Shen S, FitzGerald U, In vitro and ex vivo models of multiple sclerosis, Drug Discovery Today, 21, (9), 2016, p1504 - 1511
Rutkowska A, O'Sullivan S.A, Christen I, Zhang J, Sailer A.W, Dev K.K, The EBI2 signalling pathway plays a role in cellular crosstalk between astrocytes and macrophages, Scientific Reports, 6, 2016, p25520 -
Dev K.K, Common receptor signalling in glial & immune cells, Current Drug Targets, 17, (16), 2016, p1828-
O'Sullivan S.A, Gasparini F, Mir A.K, Dev K.K, Fractalkine shedding is mediated by p38 and the ADAM10 protease under pro-inflammatory conditions in human astrocytes, Journal of Neuroinflammation, 13, (1), 2016, p189-
O'Sullivan C, Schubart A, Mir A.K, Dev K.K, The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures, Journal of Neuroinflammation, 13, (1), 2016, p31-
Rutkowska, A. Preuss, I. Gessier, F. Sailer, A.W. Dev, K.K., EBI2 regulates intracellular signaling and migration in human astrocyte, Glia, 63, (2), 2015, p341 - 351
O'Sullivan C, Dev K.K, Galactosylsphingosine (psychosine)-induced demyelination is attenuated by sphingosine 1-phosphate signalling, Journal of Cell Science, 128, (21), 2015, p3878 - 3887
O'Connell, K.E. Thakore, J. Dev, K.K., Increased interleukin 23 (IL23) levels in schizophrenia patients treated with depot antipsychotic medication, Cytokine, 73, (1), 2014, p196-198
Sheridan, GK, Dev, KK, Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations, SCIENTIFIC REPORTS, 4, 2014, p5051-
Shrestha, R., Millington, O., Brewer, J., Dev, K.K., Bushell, T.J., Lymphocyte-mediated neuroprotection in in vitro models of excitotoxicity involves astrocytic activation and the inhibition of MAP kinase signalling pathways, Neuropharmacology, 76, (a), 2014, p184-193
David O, Mattes H, Joachim N, Dev KK., 'DERIVADOS DE FTALAZINA E ISOQUINOLINA COM ATIVIDADES MODULADORAS DO RECEPTOR DE S1P.', Dannemann, Siemsen, Bigler & Ipanema Moreira., BR/PI0810123, 2014
O'Connell, KE, Thakore, J, Dev, KK, Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine, SCHIZOPHRENIA RESEARCH, 156, (1), 2014, p1-8
Pritchard, AJ, Mir, AK, Dev, KK, Fingolimod Attenuates Splenocyte-Induced Demyelination in Cerebellar Slice Cultures, PLOS ONE, 9, (6), 2014, p0099444-
Muirhead, G. Dev, K.K., The expression of neuronal sorting nexin 8 (SNX8) exacerbates abnormal cholesterol levels, Journal of Molecular Neuroscience, 53, (1), 2014, p125 - 134
Elain, G. Jeanneau, K. Rutkowska, A. Mir, A.K. Dev, K.K., The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes, Glia, 62, (5), 2014, p725 - 735
David O, Mattes H, Joachim N, Dev KK., 'BENZAMIDAS UTILIZÁVEIS COMI MODULADORES DO RECEPTOR DE S1P. ', Dannemann, Siemsen, Bigler & Ipanema Moreira., BR/PI0811932, 2014
O'Connell, K.E. Mok, T. Sweeney, B. Ryan, A.M. Dev, K.K., The use of cytokine signature patterns: Separating drug naïve, interferon and natalizumab-treated multiple sclerosis patients, Autoimmunity, 47, (8), 2014, p505 - 511
Dutta, P., O'Connell, K.E., Ozkan, S.B., Sailer, A.W., Dev, K.K., The protein interacting with C-kinase (PICK1) interacts with and attenuates parkin-associated endothelial-like (PAEL) receptor-mediated cell deat, Journal of Neurochemistry, 130, (3), 2014, p360-373
Frei, P., Dev, K.K., Drug dealers: $20 trillion of in-licensing payments (Editorial), Drug Discovery Today, 18, (21-22), 2014, p1027-1029
O'Connell, K.E., Frei, P. , Dev, K.K., The premium of a big pharma license deal, Nature Biotechnology, 32, (7), 2014, p617-619
O'Sullivan, C., Dev, K.K. , The structure and function of the S1P1 receptor (Review), Trends in Pharmacological Sciences, 34, (7), 2013, p401-412
Pritchard, A.J., Dev, K.K. , The role of sphingosine 1-phosphate receptors in the treatment of demyelinating diseases (Review), Future Neurology, 8, (5), 2013, p569-581
Doucet MV, Levine H, Dev KK, Harkin A, Small-Molecule Inhibitors at the PSD-95/nNOS Interface have Antidepressant-Like Properties in Mice., Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 38, (8), 2013, p1575-1584
Healy LM, Sheridan GK, Pritchard AJ, Rutkowska A, Mullershausen F, Dev KK, Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes., British journal of pharmacology, 169, (5), 2013, p1114-1129
O'Connell K, Thakore J, Dev KK, Levels of S100B are raised in female patients with schizophrenia., BMC psychiatry, 13, 2013, p146
Bolia A, Gerek ZN, Keskin O, Banu Ozkan S, Dev KK, The binding affinities of proteins interacting with the PDZ domain of PICK1., Proteins, 80, (5), 2012, p1393-408
Mattes H, Joachim N, David O, Dev KK. , 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Novartis AG Corporate Intellectual Property, IN7219/DELNP/2009, 2012
Doucet MV, Harkin A, Dev KK, The PSD-95/nNOS complex: New drugs for depression?, Pharmacology and Therapeutics, 133, (2), 2012, p218-29
Sheridan GK, Dev KK, S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures., Glia, 60, (3), 2012, p382-92
Doucet MV, Harkin A, Dev KK, The PSD-95/nNOS Complex: New Drugs for Depression?, Pharmacology & Therapeutics, 133, 2012, p218 - 229
Claus Rieker, Kumlesh K. Dev, Katja Lehnhoff, Samuel Barbieri, Iwona Ksiazek, Sabine Kauffmann, Simone Danner, Heinrich Schell, Cindy Boden, Markus A. Ruegg, Philipp J. Kahle, Herman van der Putten, Derya R. Shimshek, Neuropathology in Mice Expressing Mouse Alpha-Synuclein, PLoS ONE, 6, (9, e24834), 2011
Joachim N, Mattes H, David O, Dev KK. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING ACTIVITIES.', CESAR RAMOS DE MIGUEL, MXMX/A/2009/011421, 2010
Mattes H, Joachim N, David O, Dev KK. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING ACTIVITIES.', Novartis AG Corporate Intellectual Property, EP/2148863, 2010
P. Dutta, D. Deb, L. Dargahi, D. Ivankovic, K.K. Dev, The GPR37/PAEL Receptor - Finding a Way to the Cell Surface., Drug Discovery , 7, 2010, p36 - 39
Mattes H, Joachim N, David O, Dev KK. , 'BICYCLIC S1P RECEPTOR MODULATORS.', Novartis Institutes for Biomedical Research Inc, US2010/0179153, 2010
Mattes H, Joachim N, David O, Dev KK. , 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Novartis Institutes for Biomedical Research Inc, US/2010/0197753, 2010
Mattes H, Joachim N, David O, Dev KK. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING ACTIVITIES.', Huang Gesheng Lin Bainan, CN/101679274, 2010
Mattes H, Joachim N, David O, Dev KK. , 'HTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING AVTIVITIES', Novartis AG Corporate Intellectual Property, IN/6695/DELNP/2009, 2010
Mattes H, Joachim N, David O, Dev KK. , 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Novartis Pharma AG Patent Department, EP2162427, 2010
David O, Joachim N, Mattes H, Dev KK, 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Huang Gesheng Lin Bainan, CN/101687774, 2010
H. Mattes, K.K. Dev, R. Bouhelal, C. Barske, F. Gasparini, D. Guerini, A.K. Mir, D. Orain, M. Osinde, A. Picard, C. Dubois, E. Tasdelen, S. Haessig. , Design and synthesis of selective and potent orally active S1P5 agonists., Chem Med Chem , 5, 2010, p1693 - 1696
Dev KK, Mattes H, Joachim N, David O. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING ACTIVITIES.', Davies Collison Cave Pty Ltd, AU/2008/240679, 2009
S. Chatterjee, J.D. Szustakowski, N.R. Nanguneri, C. Mickanin, M.A. Labow, A. Nohturfft, K.K. Dev* and R. Sivasankaran. , Identification of Novel Genes and Pathways Regulating SREBP Transcriptional Activity. , PLoS ONE , 4, 2009, p5197-
Dev KK, Mattes H, Joachim N, David O., 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Davies Collison Cave Pty Ltd, AU/2008/252943, 2009
Chatterjee S, Dev KK, Kuhn RR, Sivasankaran R. , 'GENES REGULATING INTRACELLULAR CHOLESTEROL TRAFFICKING AS TARGETS FOR TREATMENT OF CHOLESTEROL-RELATED DISEASES.', Novartis Pharma AG Patent Department. , EP2032599, 2009
K.K. Dev, F. Mullershausen, H. Mattes, R. Kuhn, G. Bilbe, D. Hoyer, A. Mir, Brain S1P receptors: implication for fingolimod in the treatment of multiple sclerosis., Pharmacology & Therapeutics , 117, 2008, p77 - 93
Mattes H, Joachim N, David O, Dev KK. , 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Novartis Pharma AG Patent Department, WO/2008/142073, 2008
Senechal Y, Kelly PH, Dev KK, Amyloid precursor protein knockout mice show age-dependent deficits in passive avoidance learning., Behavioural brain research, 186, (1), 2008, p126-32
Mattes H, Joachim N, David O, Dev KK. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH S1P RECEPTOR MODULATING ACTIVITIES', Novartis AG Corporate Intellectual Property, CA/2684965, 2008
Mattes H, Joachim N, David O, Dev KK. , 'BENZAMIDES USEFUL AS S1P RECEPTOR MODULATORS. Novartis Pharma AG Patent Department. ', Novartis AG Corporate Intellectual Property, CA/2686953, 2008
Mattes H, Joachim N, David O, Dev KK. , 'PHTHALAZINE AND ISOQUINOLINE DERIVATIVES WITH SLP RECEPTOR MODULATING ACTIVITIES. ', Novartis Pharma AG Patent Department, WO/2008/129029, 2008
Olson BL, Hock MB, Ekholm-Reed S, Wohlschlegel JA, Dev KK, Kralli A, Reed SI, SCFCdc4 acts antagonistically to the PGC-1alpha transcriptional coactivator by targeting it for ubiquitin-mediated proteolysis., Genes & development, 22, (2), 2008, p252-64
Osinde M, Clavaguera F, May-Nass R, Tolnay M, Dev KK, Lentivirus Tau (P301S) expression in adult amyloid precursor protein (APP)-transgenic mice leads to tangle formation., Neuropathology and applied neurobiology, 34, (5), 2008, p523-31
Senechal Y, Prut L, Kelly PH, Staufenbiel M, Natt F, Hoyer D, Wiessner C, Dev KK, Increased exploratory activity of APP23 mice in a novel environment is reversed by siRNA., Brain research, 1243, 2008, p124-33
F. Mullershausen, L.M. Craveiro, Y. Shin, M. Cortes-Cros, F. Bassilana, M. Osinde, W.L. Wishart, D. Guerini, M. Thallmair, M.E. Schwab, R. Sivasankaran, K. Seuwen and K.K. Dev. , Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors., J. Neurochemistry , 102, 2007, p1151 - 1161
Chatterjee S, Dev KK, Kuhn RR, Sivasankaran R, 'GENES REGULATING INTRACELLULAR CHOLESTEROL TRAFFICKING AS TARGETS FOR TREATMENT OF CHOLESTEROL-RELATED DISEASES', Novartis AG Corporate Intellectual Property, WO/2007/141346, 2007
M. Osinde, F. Mullershausen and K.K. Dev. , Phosphorylated FTY720 stimulates ERK phosphorylation in Astrocytes via S1P receptors. Neuropharmacology, 52, 2007, p1210 - 1218
J.F. Cryan and K.K. Dev, The Glutamatergic System as a Potential Therapeutic Target for the Treatment of Anxiety Disorders, PUBLISHED BOOK Handbook of Anxiety and Fear, Elsevier, Academic Press , 17, 2007, p269 - 301
K.K. Dev, PDZ domain protein-protein interactions: a case study with PICK1, Current Topics in Medicinal Chemistry , 7, 2007, p3 - 20
Y. Senechal, P.H. Kelly, J.F. Cryan, F. Natt, and K.K Dev., Amyloid precursor protein knockdown by siRNA impairs spontaneous alternation in adult mice. , J. Neurochemistry , 102, 2007, p1928 - 1940
K.K. Dev, Using RNAi in the Clinic, Investigational Drugs Journal , 9, 2006, p279 - 282
D. Hoyer and K. K. Dev, RNA interference as a therapeutic strategy for treating CNS disorders, Drug Discovery Today Therapeutic Strategies, 3, 2006, p451 - 456
K.K. Dev and J.M. Henley, The Schizophrenic Faces of PICK1, Trends Pharmacol Sci , 27, 2006, p574 - 579
K.K. Dev, S. Chatterjee, M. Osinde, D. Stauffer, H. Morgan, M. Kobialko, U. Dengler, H. Rueeger, B. Martoglio and G. Rovelli, Signal peptide peptidase dependent cleavage of type II transmembrane substrates releases intracellular and extracellular signals, Eur. J. Pharmacology , 540, 2006, p10 - 17
Y. Senechal, Y. Larmet and K.K. Dev, Unraveling in vivo functions of Amyloid Precursor Protein: insights from knockout and knockdown studies, Neurodegenerative Diseases , 3, 2006, p134 - 147
C. Mahé, E. Loetscher, K.K. Dev, I. Bobirnac, U. Otten and P. Schoeffter., Serotonin 5-HT7 receptors coupled to induction of interleukin-6 in human microglial MC-3 cells, Neuropharmacology, 49, 2005, p40 - 47
K.L. Madsen, T. Beuming, M.Y. Niv, C-W. Chang, K.K. Dev, H. Weinstein and U. Gether, Delineating the complex PDZ domain binding specificity of PICK1, J. Biol Chem , 280, 2005, p20539 - 20548
C. Mahé, M. Bernhard, I. Bobirnac, C. Keser, E. Loetscher, D. Feuerbach, K.K. Dev and P. Schoeffter, Functional expression of serotonin 5-HT7 receptor in human glioblastoma cell lines, Br. J. Pharmacolology, 143, 2004, p404 - 410
K.K. Dev, Making protein interactions druggable: targeting PDZ domains, Nature Reviews Drug Discovery , 3, 2004, p1047 - 1056
K.K. Dev, S. Nakanishi and J.M. Henley, The PDZ domain of PICK1 differentially accepts Protein Kinase C-á and GluR2 as interacting ligands, J. Biol Chem , 279, 2004, p41393 - 41397
E. Friedmann, M.K. Lemberg, A. Weihofen, K.K. Dev, U. Dengler, G. Rovelli and B. Martoglio, Consensus analysis of Signal Peptide Peptidase and homologous human aspartic proteases reveals opposite topology of catalytic domains compared to Presenilins, J. Biol Chem , 279, 2004, p50790 - 50798
A. Terashima, L. Cotton, K.K. Dev, G. Meyer, S. Zaman, F. Duprat, J.M. Henley, G.L. Collingridge and J.T.R. Isaac, Regulation of synaptic strength & AMPA receptor subunit composition by PICK1, J. Neuroscience , 24, 2004, p5381 - 5390
H. Hirbec, J.C. Francis, S.E. Lauri, S.P. Braithwaite, F. Coussen, C. Mulle, K.K. Dev, V. Couthino, G. Meyer, J.T.R. Isaac, G.L. Collingridge and J.M. Henley, Rapid and differential regulation of AMPA and kainite receptors at hippocampal mossy fibre synapses by PICK1 and GRIP, Neuron , 37, 2003, p625 - 638
K.K. Dev, K. Hofele, S. Barbieri, V. Buchman and H. van der Putten. , Part II: á-Synuclein and its molecular pathophysiological role in neurodegenerative disease, Neuropharmacology, 45, 2003, p14 - 44
K. Cho, J. Francis, H. Hirbec, K. Dev, M. Brown, J. Henley, and Z. I. Bashir, Regulation of kainate receptors by protein kinase C and metabotropic glutamate receptors, J. Physiology , 548, 2003, p723 - 730
N. Finney, F. Walther, P-Y. Mantel, D. Stauffer, G. Rovelli and K.K. Dev., The cellular protein level of Parkin is regulated by its ubiquitin-like domain, J. Biol Chem, 278, 2003, p16054 - 16058
K.K. Dev, H. van der Putten, B. Sommer and G. Rovelli, Part I: Parkin-associated proteins and Parkinson's Disease, Neuropharmacology, 45, 2003, p1 - 13
H. Hirbec, O. Perestenko, A. Nishimune, G. Meyer, S. Nakanishi, J.M. Henley, and K.K. Dev, The PDZ Proteins PICK1, GRIP and Syntenin bind multiple glutamate receptor subtypes, J. Biol Chem , 277, 2002, p15221 - 15224
K.K. Dev, S. Nakanishi and J. M. Henley, Regulation of mGlu7 receptors by proteins that interact with the intracellular C-terminus, Trends Pharmacol Sci , 22, 2001, p355 - 361
E. Vernon, G. Meyer, L. Pickard, K. Dev, E. Molnar, G.L. Collingridge and J.M. Henley, GABAB receptors couple directly to the transcription factor ATF4, Molecular Cell Neuroscience , 17, 2001, p637 - 645
M.I. Daw, R. Chittajallu, Z.A. Bortolotto, K.K. Dev, F. Duprat, J.M. Henley, G.L. Collingridge and J.T.R. Isaac, PDZ Proteins interacting with c-terminal GluR2/3 are involved in a PKC-dependent regulation of AMPA receptors at hippocampal synapses, Neuron , 28, 2000, p873 - 886
K.K. Dev, Y. Nakajima, J. Kitano, S. P. Braithwaite, J. M. Henley and S. Nakanishi, PICK1 interacts with and regulates PKC phosphorylation of mGluR7, J. Neuroscience , 20, 2000, p7252 - 7257
M.J. Keir, M.J. Barakat, K.K. Dev, H. Bittiger, B. Bettler and J.M. Henley, Characterisation of GABAB receptor from rat cerebellum using novel antagonist [3H]CGP 62349, Molecular Brain Research , 71, 1999, p279 - 289
K.K. Dev, A. Nishimune, J.M. Henley and S. Nakanishi, The protein kinase Cá binding protein PICK1 interacts with short but not long form alternative splice variants of AMPA receptor subunits, Neuropharmacology, 38, 1999, p635 - 644
K.K. Dev and J.M. Henley, The Regulation of AMPA receptor binding sites, Molecular Neurobiology , 17, 1998, p33 - 58
K.K. Dev, T. Honoré and J.M. Henley, Different effects of Phospholipase A2 on agonist binding to hippocampal, cortical and recombinant homomeric AMPA receptors, Neuroscience Letters , 246, 1998, p25 - 28
K.K. Dev, C. Foged, H. Andersen, T. Honoré and J.M. Henley, High affinity binding sites for [125I]-labelled pancreatic secretory phospholipase A2 in rat brain, Molecular Brain Research , 49, 1997, p120 - 126
K.K. Dev, V. Petersen, T. Honoré and J.M. Henley, Pharmacology and regional distribution of [3H] 6-nitro-7-sulphamoylbenzo(F)quinoxaline-2-3 dione ([3H]NBQX) binding to rat brain, J. Neurochemistry , 67, 1996, p2609 - 2612
R. Chittajallu, M. Vignes, K.K. Dev, J.M. Barnes, G.L. Collingridge and J.M. Henley, Regulation of glutamate release by presynaptic kainate receptors in the hippocampus, Nature, 379, 1996, p78 - 81
K.K. Dev, P.J. Roberts, and J.M. Henley, Characterisation of the interaction between guanyl nucleotides and AMPA receptors in rat brain, Neuropharmacology, 35, 1996, p1583 - 1593
K.K. Dev, T. Honoré and J.M. Henley, Phospholipase A2 down-regulates the affinity of [3H]AMPA binding to rat cortical membranes, J. Neurochemistry , 65, 1995, p184 - 191
Dev KK and Morris BJ, Modulation of a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) binding sites by nitric oxide, Journal of Neurochemistry , 63, 1994, p946 - 952
Barnes JM, Dev KK and Henley JM, Cyclothiazide unmasks AMPA-evoked stimulation of [3H]-L-glutamate release from rat hippocampal synaptosomes, Br. J. Pharmacology , 113, 1994, p339 - 341
Non-Peer-Reviewed Publications
Dev KK, 6th Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci., 186, 2017, p281 - 298
Dev KK, 5th Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci., 185, 2016, p169 - 185
Dev KK, 4th Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci., 184, 2015, p1 - 18
Dev KK, Neurology, Professor Kumlesh Dev sets out Ireland's position on brain disease. Irish Independent (Supplement), 2015, -
Dev KK, 3rd Annual Meeting. Frontiers in Neurology Ireland (FIN), Irish J Med. Sci. , 183, 2014, p71 - 85
Dev KK, 2nd Annual Meeting. Block MS Ireland. Neuroprotection: At the cellular, in vivo and clinical level., Irish J Med. Sci., 182, 2013, p1 - 13
Research Expertise
Description
My research is focused in areas of Drug Development and Neuroscience. My research integrates fields of molecular biology, cell science, and drug discovery. It integrates the areas of cell biology, medicine and pharmaceuticals. I established the Drug Development group at Trinity, which investigates mechanisms underlying brain diseases, particularly demyelinating diseases such as Multiple Sclerosis, and also with a focus on rare paediatric illnesses including Krabbes disease (KD). KD causes fatality in infants and has no cure. My group has identified new compounds, repositioned marketed drugs, developed novel nanoparticle technology and created nasal delivery methods that demonstrate efficacy models of KD. These findings are published in top-tier neuroscience and neurotherapeutic journals and are of international recognition. This research is translational, where the developed technologies are on a potential path of clinical development, subject of patent application, commercialisation and the basis of EU grant applications, supported by Enterprise Ireland. My research has transformed our understanding of how marketed drugs used in Multiple Sclerosis work, and how they directly regulate brain cells. This work is pioneering, highly cited and uncovered novel cell mechanisms leading to development of new therapeutic strategies. This work demonstrates an ongoing transformational nature of my activities. My research is competitively recognised and well supported by national and international funding agencies as well as multinational pharmaceutical industry and biotech. I have been awarded over 5.7 million in funding, published almost 100 papers and have an H-index of over 40. I am a board member and reviewer of several international journals, advisor and consultant to large pharmaceutical and biotech companies and I have been President of Frontier of Neurology Ireland for 7 years, bringing to Ireland and Trinity links from across Europe and US, and bringing support from multiple large pharma and research funding agencies. My work has also been highlighted in national press in the area of neurology and drug development. I have significant expertise in drug development and a global network within multiple pharma and biotech industry. I have provided leadership to large research and drug discovery projects and successfully delivered follow-on compounds of marketed drugs, for Multiple Sclerosis. I have published extensively in my area of research of brain cell biology, specifically glial cells. The journal Glia is the highest journal in this field in which my research is being published on a yearly basis. A pubmed search in my focussed area indicates 10% of articles being from my group, many are highly cited. The approaches used by my group, integrating human brain cells and brain slice studies are also unique. The drug testing platform established in my group attracts multiple industry collaborations. I am regularly invited as a Consultant to guide and review drug development projects. I have provided Consultant assistance to drug development of nearly 100 various pharma and biotech companies. With these activities, I have a world leader recognition in my area of drug development. My mission is to teach within the emerging field of drug development as well as develop new medicines.Recognition
Representations
Consortium Member, Horizon 2020, EU-KIC, EU-EIT Health Ageing PhD School, (EU-collaborative network providing training opportunities to PhD students in Trinity)
President, Frontiers in Neurology Ireland (FIN) (Held for 7 years, in recognition within area of Drug Development & Neurology)
Council Member, Society for Neuroscience Ireland (Held for 3 years, developing travel grant applications in the society)
Council Member, Swiss Tissue Culture Society (Held for 2 years, international society focused on cell-based drug discovery)
Member, Society for Neuroscience (Recognised as the major neuroscience society globally)
Editorial Board Member, Brain, Behavior, and Immunity (Impact Factor 7.217, Quartile Q1, 16/156 Psychiatry Journals)
Editorial Board Member, Scientific Reports (Impact Factor 4.379, Quartile Q1)
Editorial Board Member, Journal of Biological Chemistry (Impact Factor 5.157, Quartile Q1, In top 75% Biochem & Cell Journals)
Editor, Frontiers in Behavioral Neuroscience (Drug Development in Rare Demyelinating Diseases), (4th cited open access in Neurosci)
Editor, Special Issue In Cancers (Cangliomics - Repositioning Drugs for Cancer Gliomas), (Impact Factor 6.639)
Editor, Special Issue In Neuropharmacology (Lipid Sensing G Protein-Coupled Receptors in the CNS), (Impact Factor 5.251)
Editor, Special Issue In Current Drug Targets (Common Receptor Signalling in Glial and Immune Cells), (Impact Factor 3.030)
External Examiner, MSc Clinical Neuroscience, NUI Galway, Ireland
Visiting Professor, Dept. Food & Drug Sciences, University of Parma, Italy
External Examiner, PhD Thesis (External Examiner of multiple PhD Thesis, approx. 1-2 per year)
External Consultant, Pharma and Biotech Industries (Consultant Role in scientific review of multiple biotech and pharma companies)
Awards and Honours
External Examiner, MSc Clinical Neuroscience, NUI Galway, Ireland (Recognises leadership in research and teaching in Neuroscience)
Visiting Professor, Dept. Food & Drug Sciences, University of Parma, Italy
Fellow, Trinity College Dublin (FTCD)
Wellcome Trust, Over 0.65 million, Multiple Awards
Enterprise Ireland, Over 0.14 million, Multiple Awards
Health Research Board, Over 1.09 million, Multiple Awards
Industry Over 0.96 million, Multiple Awards
Irish Research Council, Over 0.14 million Multiple Awards
Science Foundation Ireland, Over 0.28 million, Multiple Awards
Charities, Over 0.60 million, Multiple Awards
Consortium Trinity Lead, Horizon 2020, EU-KIC, EU-EIT Health Ageing PhD School
Work Package Lead and Course Director, HEA, Human Capital Initiative (Pillar 3)
Work Package Lead and Course Director, HEA, Human Capital Initiative (Pillar 1)
Project Collaborator, HEA, PRTLI, Ireland Award
Editor, Special Issue, Frontiers in Behavioral Neuroscience
Editor, Special Issue, Cancers
Editor, Special Issue, Neuropharmacology
Editor, Special Issue, Current Drug Targets
Memberships
Consortium Member, Horizon 2020, EU-KIC, EU-EIT Health Ageing PhD School
Fellow, Trinity College Dublin (FTCD)
President, Frontiers in Neurology Ireland (FIN)
Council Member, Society for Neuroscience Ireland
Council Member, Swiss Tissue Culture Society
Member, Society for Neuroscience
Editorial Board Member, Brain, Behavior, and Immunity
Editorial Board Member, Scientific Reports
Editorial Board Member, Journal of Biological Chemistry